Service Quote Request
Please fill out the form below with your detailed inquiry.
How intron selection can improve mRNA processing, transgene expression, and viral vector performance
Achieving strong and sustained transgene expression is one of the most important considerations in recombinant adeno-associated virus (rAAV) vector design. While promoters, enhancers, and regulatory elements such as the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) play essential roles in controlling gene expression, another important component is often overlooked: the intron.
Introns are noncoding sequences that are transcribed into precursor messenger RNA (pre-mRNA) and subsequently removed through RNA splicing. Although introns do not encode proteins, their presence within an expression cassette can significantly influence gene expression by improving mRNA processing, nuclear export, transcript accumulation, and translation.
In mammalian expression vectors, introns are commonly positioned downstream of the promoter and upstream of the transgene coding sequence. Properly designed introns may substantially improve recombinant protein expression compared with otherwise identical intronless constructs.
This article reviews the most commonly used introns in AAV and mammalian expression vectors, compares their characteristics, and discusses practical considerations for selecting an appropriate intron for gene delivery applications.
The enhancement of gene expression by introns is often referred to as intron-mediated enhancement (IME). Several molecular mechanisms contribute to this phenomenon.
Improved mRNA Splicing and Processing
Functional introns recruit components of the spliceosome, facilitating the processing of pre-mRNA into mature mRNA. Efficient splicing can promote proper transcript maturation and increase the availability of functional mRNA.
Enhanced Nuclear Export of mRNA
Splicing can facilitate recruitment of RNA-binding proteins and export-associated complexes, improving the transport of mature mRNA from the nucleus into the cytoplasm, where protein synthesis occurs.
Increased mRNA Accumulation and Stability
Certain introns can increase steady-state mRNA abundance through improved processing, export, or other transcript-dependent mechanisms.
Enhanced Protein Expression
Through the combined effects of transcriptional and posttranscriptional regulation, intron-containing expression cassettes can produce substantially higher protein levels than corresponding intronless constructs.
However, the extent of enhancement depends on the intron sequence, promoter, transgene, host cell type, and target tissue. Not all introns enhance expression equally, and some may provide little benefit or even negatively affect expression in particular vector configurations.
The human β-globin/immunoglobulin (IgG) chimeric intron is one of the best-established artificial introns used in mammalian expression vectors.
It combines splice-processing elements derived from the human β-globin gene and an immunoglobulin heavy-chain gene to promote efficient RNA splicing.
This intron architecture is incorporated into widely used mammalian expression systems, including Promega’s pCI and pCI-neo vectors.
Key characteristics:
Potential applications:
The β-globin/IgG chimeric intron is a useful candidate for AAV vectors employing promoters such as CMV, EF1α, hSyn, and CaMKIIα, provided that its performance is validated in the intended expression cassette.
Overall assessment: An excellent general-purpose candidate for enhancing transgene expression in mammalian and recombinant AAV vectors.
The Minute Virus of Mice (MVM) intron is a particularly attractive option for AAV vector engineering because of its compact size.
Compact introns are advantageous for recombinant AAV vectors, which have a limited genome packaging capacity of approximately 4.7 kb, including the inverted terminal repeats (ITRs).
Certain engineered MVM-derived introns are approximately 67–97 bp long, depending on the precise configuration.
Key characteristics:
In some liver-directed AAV expression studies, MVM-derived introns produced substantial increases in transgene expression compared with intronless controls. However, these results should not be assumed to apply to every promoter, target tissue, or transgene.
Overall assessment: One of the most promising compact introns for AAV vectors, especially when packaging capacity is a major concern.
SV40-derived introns have a long history of use in mammalian expression vectors and are incorporated into various recombinant expression systems.
Both native and modified SV40 introns have been studied for improving mRNA processing and transgene expression.
Key characteristics:
SV40 introns may provide moderate expression enhancement, although their relative performance varies with the experimental system.
Overall assessment: A practical, well-characterized alternative for mammalian and AAV vector engineering.
Adenovirus/immunoglobulin hybrid introns combine splice donor and acceptor elements from different biological sources to improve RNA processing.
Certain engineered versions incorporate adenovirus-derived splice donor elements together with immunoglobulin-derived splice acceptor sequences.
Key characteristics:
Because individual hybrid introns differ in sequence and length, the precise construct should be identified before making comparisons.
Overall assessment: A promising alternative to β-globin-derived chimeric introns when optimizing transgene expression.
Rabbit β-globin-derived introns are well established in mammalian expression systems, particularly in constructs incorporating chicken β-actin regulatory elements.
A prominent example is the CAG promoter system, which combines the cytomegalovirus immediate-early enhancer with chicken β-actin promoter-associated elements and a splice-processing region.
CAG-derived expression cassettes are widely used to drive strong transgene expression across many mammalian cell types.
Key characteristics:
It is important to recognize that many full-length CAG promoter constructs already contain an intron. Therefore, adding another intron downstream may provide little additional benefit and could introduce unwanted splice interactions.
Overall assessment: Especially relevant to CAG-derived expression cassettes, where intron-containing regulatory regions are often already part of the promoter architecture.
Natural human β-globin introns have also been incorporated into mammalian expression vectors.
These introns contain well-characterized splice donor and acceptor elements and have contributed to the development of multiple engineered intron systems.
Key characteristics:
Overall assessment: A well-characterized intron source that remains relevant for mammalian expression and the design of artificial chimeric introns.
Human coagulation factor IX introns have received considerable attention in liver-directed gene therapy, particularly in the development of AAV vectors for hemophilia B.
Native and engineered FIX intron sequences have been incorporated into expression cassettes to improve FIX production.
Key characteristics:
Because of AAV packaging limitations, compact engineered FIX intron sequences may be preferable to larger native intronic regions.
Overall assessment: Particularly relevant to liver-directed gene therapy and expression of coagulation factors, but not necessarily the best universal choice for unrelated transgenes.
The optimal intron depends on the promoter, target tissue, available packaging space, and intended transgene.
For neuron-targeted AAV vectors using the human synapsin (hSyn) or CaMKIIα promoter, compact introns are worth investigating.
Recommended candidates for experimental comparison include:
For neuronal expression cassettes, the most important consideration is whether an intron enhances expression in the intended neuronal population without introducing unwanted splice products or disrupting cell-type specificity.
The CMV and EF1α promoters are widely used for constitutive transgene expression.
Potential intron candidates include:
Some EF1α promoter constructs already incorporate part of the natural EF1A gene’s first exon and intron. Adding a separate intron should therefore be considered only after examining the complete regulatory sequence.
Liver-directed AAV vectors frequently use the thyroxine-binding globulin (TBG) promoter or regulatory elements combining the apolipoprotein E enhancer with the human α1-antitrypsin promoter (ApoE/hAAT).
Potential candidates include:
The choice should account for expression in hepatocytes, transcript integrity, and the size of the complete AAV genome.
Full-length CAG expression cassettes frequently include an intron as part of their regulatory architecture.
However, compact CAG variants, including some small CAG (smCAG) constructs, may have shortened or deleted intronic regions.
For these vectors, the first step is to confirm whether the existing cassette already contains a functional intron.
Adding an additional intron may be useful in certain designs, but this must be evaluated experimentally rather than assumed to improve expression.
Introns intended to enhance transgene expression are commonly inserted within the transcribed 5′ untranslated region (5′ UTR), between the promoter-associated transcription start site and the transgene coding sequence.
A typical expression cassette may be organized as follows:
5′ ITR → Promoter → Intron → Transgene CDS → WPRE → PolyA → 3′ ITR
The intron must be located within the transcribed region so that it can be incorporated into pre-mRNA and subsequently removed through splicing.
Important design considerations include:
An intron that works well in one expression cassette may not provide the same benefit when transferred to another promoter or transgene.
Both introns and WPRE are commonly used to improve transgene expression, but they act through different, partially overlapping molecular mechanisms.
Introns primarily contribute through RNA splicing-associated processes, which can influence transcript maturation, nuclear export, mRNA accumulation, and protein expression.
WPRE is a posttranscriptional regulatory element generally positioned downstream of the transgene coding sequence and upstream of the polyadenylation signal. It can enhance expression through effects on RNA processing, accumulation, and export, depending on the vector context.
Because introns and WPRE have distinct regulatory roles, they may be combined within a single expression cassette.
For example:
5′ ITR → hSyn Promoter → Chimeric Intron → GFP → WPRE → hGH PolyA → 3′ ITR
However, the presence of both elements does not guarantee additive or synergistic enhancement. Their combined performance should be measured experimentally.
Although intron addition is a relatively straightforward approach to expression cassette engineering, several factors must be considered.
Recombinant AAV vectors generally accommodate approximately 4.7 kb of DNA, including both ITRs, although practical packaging performance depends on the construct.
For vectors approaching this limit, compact introns such as MVM-derived sequences may provide an advantage over larger introns.
Expression enhancement varies with transgene sequence and the host cell’s RNA-processing machinery.
An intron that performs well in hepatocytes may not perform equally well in neurons, skeletal muscle cells, or other tissues.
Incorrect intron removal can result in aberrant mRNA, reduced protein expression, or unintended protein products.
Splicing efficiency should therefore be verified, especially for novel introns or modified constructs.
Before introducing an additional intron, researchers should inspect the complete vector sequence.
Promoter systems such as full-length CAG and some EF1α configurations already incorporate intronic elements.
The most reliable way to identify the optimal intron is to compare otherwise identical expression cassettes containing different introns.
An appropriate comparison may include an intronless control, a β-globin/IgG chimeric intron, and an MVM-derived intron.
Evaluation can include correctly spliced mRNA abundance, protein expression, transgene function, and expression persistence in the intended target cells.
For laboratories developing custom recombinant AAV vectors, three intron categories deserve particular consideration.
First choice: Human β-globin/IgG chimeric intron
This is a strong starting candidate for general-purpose mammalian expression cassette design. Its established use in commercial vector systems makes it attractive when selecting a conventional intron architecture.
Second choice: MVM-derived compact intron
The MVM intron is especially attractive when the available AAV packaging space is limited. Its small size makes it useful for evaluating expression enhancement without substantially increasing vector genome length.
Third choice: Adenovirus/IgG hybrid intron
The adenovirus/IgG hybrid intron provides another engineered splice-processing architecture worth comparing in applications where maximizing expression is a priority.
These recommendations should be considered candidate selections rather than a universal performance ranking. No single intron has been established as optimal across all AAV serotypes, promoters, transgenes, and tissues.
Introns are important regulatory elements in mammalian and recombinant AAV expression cassette engineering. When appropriately designed and positioned, they can improve RNA processing, increase mature mRNA accumulation, and enhance transgene expression.
Among the commonly used candidates, human β-globin/IgG chimeric introns, MVM-derived introns, SV40 introns, adenovirus/IgG hybrid introns, rabbit β-globin introns, and human FIX introns offer different advantages depending on the experimental application.
For compact AAV vectors, MVM-derived introns are particularly appealing because of their small size. For general mammalian expression systems, the β-globin/IgG chimeric intron remains a useful, established starting point.
Ultimately, the best intron is determined by the complete expression cassette and its intended biological application, rather than by intron sequence alone.
At SignaGen Laboratories, our custom AAV vector development and production services support a wide variety of promoter, transgene, regulatory-element, and AAV capsid configurations. Incorporating an appropriately selected intron can be an important consideration when optimizing vectors for neuroscience, liver-directed gene delivery, muscle research, and other biomedical applications.
Learn more about our custom AAV production services:
